The Québec-Ontario life sciences corridor
A dense network of AI institutes, research hospitals and medtech firms is positioning the corridor as a global meeting point for health innovation

Canada’s life sciences sector is gaining momentum across pharmaceuticals, medical devices, biotechnology and artificial intelligence (AI), as research moves towards commercial scale. The country is already a global leader in digital radiography, in-vitro diagnostics, cardiovascular devices, dental implants and home healthcare products, and its researchers are leveraging technology to break new ground.
At the centre of this activity is the Québec-Ontario Life Sciences Corridor, one of North America’s most concentrated networks of research hospitals, universities, start-ups and multinational firms. Anchored by institutions such as the Vector Institute in Toronto and Mila, the Québec AI Institute in Montréal, the corridor has become a natural meeting point for global organisations.
The strength of the corridor lies not only in scale, but also in specialisation. In Ottawa, for example, a biomechanical research cluster is renowned for its progress in merging biomechanics and data science to optimise the performance of people in the workplace, in sports and in their daily lives. One example of the blending of technology and research is markerless motion capture, which tracks human movement to develop models in real time.
“Technology is moving so fast in various other fields, like computer vision and wearable sensors … and that continues to bleed into our research and vice versa,” says Ryan Graham, associate professor and research chair in biomechanics and data science for human health and performance at the University of Ottawa.
The trailblazers
Canada has a long list of companies pushing the frontiers of medical research.
Vancouver-based AbCellera Biologics has a mission to “search, decode and analyse natural immune systems to find antibodies” to be developed by its partners into new life-saving drugs.
Entos Pharmaceuticals, based in Edmonton, is developing DNA vaccines to solve pressing health challenges—using its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform.
Canada’s competitive edge rests on deep pools of talent, world-class research and development, and high-growth clusters in fields such as image-guided therapies and artificial intelligence. These strengths are drawing global organisations to its life sciences hubs, where conferences and B2B exchanges offer access to international networks, early-stage innovations and made-in-Canada solutions.